Fierce Health Payer September 16, 2021
Dave Muoio

Some safety net hospitals are charging payers a median 3.8 times more than the purchase price for oncology drugs, according to an analysis of hospital price transparency data.

Across a selection of 59 oncology treatment and supportive drugs, the spread between the discounted purchase price and the charged price ranged from a 2.4 times median increase to an 11 times median increase at 340B disproportionate share hospitals, the Community Oncology Alliance (COA) wrote in a report published Tuesday.

The increases in pricing can vary broadly from facility to facility and even within a single hospital, according to the report. Further, 340B hospitals frequently did not list a treatment’s biosimilar and reported charging nearly identical rates to cash-paying patients as they...

Today's Sponsors

ZeOmega
Holon
Transcarent

Today's Sponsors

Crossover Health
Qure4u

Today's Sponsor

Institute for Healthcare Improvement

 
Topics: Biotechnology, Health System / Hospital, Pharma, Pharma / Biotech, Provider, Survey / Study, Trends
340B Drug Pricing Program and Hospital Provision of Uncompensated Care
340B hospitals mark up cancer drugs 3.8X for commercially insured patients, study finds
Report claims 340B hospitals are leveraging discounts to increase profits from cancer drugs
11 health systems buy minority stake in pharma company to boost domestic production
Exploring 2022 Trends in Health and Hospital Drug Spending With Vizient